top of page
Hope4ATRT Logo

Clinical Trial Navigation through Carebox Connect!

Hope4ATRT is proud to partner with Carebox, a free and confidential service that simplifies the search for Atypical Teratoid Rhabdoid Tumor (ATRT) clinical trials.

Patients, caregivers, and healthcare professionals can easily create a profile by answering a few questions. Carebox then matches you with relevant ATRT clinical trials that might be a good fit, empowering you to make informed decisions about your care.

Important to Know:

  • Carebox protects your privacy and does not share your information with trial sites.

  • Matching with a trial doesn't guarantee enrollment, and participation is always voluntary.

  • You can stop using Carebox at any time.

Start your search for potential ATRT clinical trials today!

WHAT ARE CLINICAL TRIALS?

Clinical trials are research studies that test new approaches to treatment. They help doctors determine if a new treatment is safe, effective, and potentially better than current options. Participating in a clinical trial can offer patients access to cutting-edge treatments and the chance to contribute to advancements in brain cancer care. 

 

You can also learn more through these resources:

ABOUT ATRT

ATRT is a very rare, fast-growing tumor of the brain and spinal cord. The disease commonly affects children age 3 or younger but can also affect older children and adults. Learn more.

ABOUT HOPE4ATRT

Drs. Kosj and Jaymi Yamoah started Hope4ATRT after walking through their own cancer journey as a family. In 2015 their almost three-year-old son, Zion, was diagnosed with a rare and aggressive form of brain cancer known as Atypical Teratoid Rhabdoid Tumor (ATRT). Even as an oncologist himself, Dr. Yamoah was dismayed to learn how limited resources were for this rare disease. After the devastating loss of Zion, his parents were compelled to help fund innovative research, and be a resource for families in the fight against ATRT.

 

Hope4ATRT's mission is two-fold:

  • to direct resources to parents of children with ATRT

  • to raise funding for innovative research specifically for ATRT

 

To learn more visit Hope4atrt.org , and connect on Facebook , Instagram and YouTube.

Open Clinical Trials

BrainChild-04: Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy for Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors

Purpose of this clinical trial:

The BrainChild-04 study is investigating Seattle Children’s Therapeutics’ first CAR T-cell product that targets four antigens simultaneously: B7-H3, EGFR806, HER2 and IL13-zetakine.  This is the first known CAR T-cell product in the world to target four antigens at the same time by delivering CAR T cells directly to the brain.

TAZNI: A Phase I/II Combination Trial of Tazemetostat with Nivolumab and Ipilimumab for Children with INI1-Negative or SMARCA4-Deficient Tumors

Purpose of this clinical trial:

This research study involves a combination of three drugs given together as a possible treatment for malignant rhabdoid tumor, atypical teratoid rhabdoid tumor, epithelioid sarcoma, chordoma or other tumors that are deficient in one of two possible proteins, either INI-1 (SMARCB1) or SMARCA4.




PNOC025: Magrolimab in Children and Adults with Recurrent or Progressive Malignant Brain Tumors

Purpose of this clinical trial:

The goal of this study is to test the safety and efficacy of magrolimab in children and adults with recurrent or progressive malignant brain tumors. Magrolimab is a novel antibody anticancer therapeutic agent targeting a certain protein called CD47. Binding of magrolimab to CD47 on target malignant cells blocks the "don't eat me" signal by cancer cells and enhances tumor cell phagocytosis.

MEMMAT: Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma and ATRT

Purpose of this clinical trial:

The goal of this study is to provide additional therapy options for children with recurrent or progressive medulloblastoma, ependymoma and ATRT, for whom no known curative therapy exists, by prolonging survival while maintaining good quality of life. The primary objective of the MEMMAT trial is to evaluate the activity of this multidrug antiangiogenic approach in previously treated children and young adults

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

Purpose of this clinical trial:

This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested.

9-ING-41 in Pediatric Patients With Refractory Malignancies

Purpose of this clinical trial:

9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in pediatric patients with advanced malignancies.

CLOVER-2: Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma

Purpose of this clinical trial:

The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.

Nivolumab-Ipiliumab: Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Purpose of this clinical trial:

The main purpose of this study is to determine the safety and effectiveness of nivolumab and ipilimumab for patients with relapsed or refractory INI1- negative tumors.  Patients with multiple types of solid tumors and brain tumors will be included as part of this study.  Patients will only be eligible for this study if their tumor has shown a mutation/deletion of a gene that is known to suppress tumor growth called INI1.

Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Brain Tumors

Purpose of this clinical trial:

The goal of this clinical research study is to establish the safety of simultaneous infusions of methotrexate and etoposide into the fourth ventricle of the brain or resection cavity in patients with recurrent malignant posterior fossa brain tumors. Patients' disease must have originated in the posterior fossa of the brain.

MV-NIS: Modified Measles Virus for Children and Young Adults with Recurrent ATRT

Please note, this study has closed to accrual and is no longer accepting patients.


Purpose of this clinical trial:

The main purpose of MV-NIS is to study the effects of the safety and appropriate dose level of the modified measles virus (MV-NIS) in children and young adults with recurrent (disease has returned) medulloblastoma or ATRT

PBTC-051: Phase I Study of APX005M in Pediatric CNS Tumors

Please note, this study is closed and is no longer accepting patients.


Purpose of this clinical trial:

The main purpose of this study is to determine the best dose and side effects of a new drug called APX005M in treating children and young adult patients with brain cancer that is growing, spreading or getting worse.

PBTC-050: Phase I Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors

Please note, this study is closed and is no longer accepting patients.


Purpose of this clinical trial:

The main purpose of this study is to determine the best dose and side effects of a combination of drugs and to see how well the work in treating children and young adults with brain cancer that has come back or did not respond to treatment. These drugs may stop the growth of tumor cells by inhibiting the enzymes needed for the cells to grow. Giving ribociclib and everolimus together may work better in treating these aggressive types of brain tumors.

bottom of page